Securities Fraud

Introduction

Securities fraud encompasses a broad range of deceptive practices in connection with the purchase or sale of securities. The primary federal antifraud provision is SEC Rule 10b-5, promulgated under Section 10(b) of the Securities Exchange Act of 1934. Rule 10b-5 prohibits fraudulent conduct in connection with the purchase or sale of any security and implies a private right of action for investors who are injured by securities fraud.

Rule 10b-5

Rule 10b-5 makes it unlawful for any person, by use of interstate commerce, to employ any device, scheme, or artifice to defraud; to make any untrue statement of a material fact or to omit a material fact necessary to make the statements not misleading; or to engage in any act, practice, or course of business that operates as a fraud or deceit in connection with the purchase or sale of any security.

The rule reaches a wide range of conduct, including fraudulent misrepresentations, deceptive omissions, and market manipulation. The Supreme Court has held that the rule applies to fraud in connection with the purchase or sale of any security and that it protects both buyers and sellers.

Materiality

To establish a violation of Rule 10b-5, the plaintiff must prove that the defendant made a misrepresentation or omission of a material fact. A fact is material if there is a substantial likelihood that a reasonable investor would consider it important in making an investment decision.

The Supreme Court in Basic Inc. v. Levinson (1988) defined materiality as a substantial likelihood that the disclosure of the omitted fact would have been viewed by the reasonable investor as having significantly altered the total mix of information available. Materiality is assessed from the perspective of the reasonable investor.

Scienter

Scienter is the intent to deceive, manipulate, or defraud. The plaintiff must prove that the defendant acted with scienter —either knowing of the falsity of the statement or acting with reckless disregard for its truth. Negligence is not sufficient to establish scienter under Rule 10b-5.

The Private Securities Litigation Reform Act (PSLRA) requires the plaintiff to plead scienter with particularity, stating facts giving rise to a strong inference that the defendant acted with the required state of mind. The strong inference must be cogent and at least as compelling as any opposing inference of nonfraudulent intent.

Private Right of Action

Rule 10b-5 implies a private right of action for investors who are injured by securities fraud. To bring a private action, the plaintiff must prove: a material misrepresentation or omission; scienter; a connection with the purchase or sale of a security; reliance; economic loss; and loss causation.

Reliance may be presumed under the fraud-on-the-market theory from Basic v. Levinson, which allows plaintiffs to rely on the integrity of the market price in an efficient market. Loss causation requires the plaintiff to prove that the misrepresentation caused the economic loss.

The PSLRA

The Private Securities Litigation Reform Act of 1995 (PSLRA) imposed significant procedural requirements on securities fraud class actions. The PSLRA requires the lead plaintiff with the largest financial interest, imposes a stay of discovery during motions to dismiss, requires heightened pleading of scienter, and provides a safe harbor for forward-looking statements.

Conclusion

Securities fraud is regulated primarily through SEC Rule 10b-5, which prohibits fraudulent conduct in connection with securities transactions. The elements of materiality, scienter, reliance, and loss causation define the cause of action. The PSLRA imposes heightened procedural requirements to limit abusive securities litigation.